<DOC>
	<DOCNO>NCT00052052</DOCNO>
	<brief_summary>Study GIPF-004 open-label , multicenter study enroll approximately 250 patient complete Protocol GIPF-001 . The purpose study assess safety efficacy continue IFN-gamma 1b therapy well-defined cohort patient 48 week .</brief_summary>
	<brief_title>An Open-Label Study Safety Efficacy Subcutaneous Recombinant Interferon-Gamma 1b ( IFN-Gamma 1b ) Patients With Idiopathic Pulmonary Fibrosis ( IPF )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Male Female Idiopathic Pulmonary Fibrosis 2079 year Must participate InterMune protocol GIPF001 study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>idiopathic pulmonary fibrosis</keyword>
	<keyword>IPF</keyword>
</DOC>